التفاصيل البيبلوغرافية
| العنوان: |
Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin |
| المؤلفون: |
Miya, Aika, Nakamura, Akinobu, Cho, Kyu Yong, Kawata, Shinichiro, Nomoto, Hiroshi, Nagai, So, Sugawara, Hajime, Taneda, Shinji, Tsuchida, Kazuhisa, Omori, Kazuno, Yokoyama, Hiroki, Takeuchi, Jun, Aoki, Shin, Kurihara, Yoshio, Atsumi, Tatsuya, Miyoshi, Hideaki |
| المساهمون: |
Mitsubishi Tanabe Pharma Corporation |
| المصدر: |
Journal of Diabetes Investigation ; volume 12, issue 8, page 1395-1399 ; ISSN 2040-1116 2040-1124 |
| بيانات النشر: |
Wiley |
| سنة النشر: |
2021 |
| المجموعة: |
Wiley Online Library (Open Access Articles via Crossref) |
| الوصف: |
Aims/Introduction To identify the effect of combination therapy with a dipeptidyl peptidase‐4 inhibitor and a sodium–glucose cotransporter 2 inhibitor compared with switching from a dipeptidyl peptidase‐4 inhibitor to a sodium–glucose cotransporter 2 inhibitor on improving the glucose variability in patients with or without impaired endogenous insulin secretion. Materials and Methods A secondary analysis regarding the relationship between endogenous insulin secretion and the change in mean amplitude of glycemic excursions (ΔMAGE) was carried out in a multicenter, prospective, randomized, parallel‐group comparison trial that enrolled patients with type 2 diabetes who had been taking teneligliptin and were treated by switching to canagliflozin (SWITCH) or adding canagliflozin (COMB). Participants were categorized into the following four subgroups: SWITCH or COMB and high or low fasting C‐peptide (CPR) divided at baseline by the median. Results ΔMAGE in the COMB group was greatly improved independent of a high or low CPR (−29.2 ± 28.3 vs −20.0 ± 24.6, respectively; P = 0.60). However, ΔMAGE was not ameliorated in the low CPR SWITCH group, and the ΔMAGE was significantly smaller than that in the high CPR COMB group ( P < 0.01). Conclusions COMB would be a better protocol rather than switching teneligliptin to canagliflozin to improve daily glucose variability in patients with impaired endogenous insulin secretion. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1111/jdi.13479 |
| الإتاحة: |
https://doi.org/10.1111/jdi.13479Test |
| حقوق: |
http://creativecommons.org/licenses/by-nc/4.0Test/ |
| رقم الانضمام: |
edsbas.904D356C |
| قاعدة البيانات: |
BASE |
